U.S. Pharmacist Weekly News

December 7, 2022

COVID-19 Reinfection Adds Significant Risk to Multiple Organ Systems

Despite misconceptions that prior COVID-19 infections can keep patients from having severe cases in the future, a new study suggested that recurrent cases pile on the risk of adverse health conditions in multiple organ systems. Reinfected patients were twice as likely to die and three times more likely to be hospitalized. Learn more about the results of this study.

Risk for Drug Interactions in Breast Cancer Hormone Adherence

How does the potential for drug-drug interactions affect adherence to endocrine therapy among patients with breast cancer? Even though a recent study did not find that the potential for drug-drug interactions was affecting adherence to endocrine therapy among breast cancer patients, the study noted that many women have them and need to be carefully assessed. Read more.

Pharmacists Still Plagued by Hard-to-Get Medications

Drug shortages are continuing in the United States since the start of the COVID-19 pandemic, and—while hospitals are struggling to obtain acute-care drugs—community pharmacists still cannot get orders of common outpatient drugs such as the attention-deficit/hyperactivity disorder drug Adderall and the antibiotic amoxicillin. Nearly 98% of community pharmacies stated that they were facing those challenges. Read more.

Pharmacist Video Series: Xatmep

In this latest Pharmacist Recommendation Series, U.S. Pharmacist Editor-in-Chief Robert Davidson interviews compounding/specialty pharmacist Amanda Ye, PharmD, RPh, who reviews Xatmep, the only FDA-approved, ready-to-use methotrexate option for pharmacists. Click here to view video.